Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade

Description of Altumomab Biosimilar - Anti-CEACAM5, CD66e mAb - Research Grade

Introduction:

Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade is a monoclonal antibody that has been developed as a biosimilar to the original antibody, Altumomab. This antibody specifically targets CEACAM5, also known as CD66e, a cell surface protein that is overexpressed in various types of cancers. In this article, we will discuss the structure, activity, and potential applications of this biosimilar.

Structure:

Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade is a recombinant monoclonal antibody that is produced in a mammalian cell expression system. It is composed of two heavy chains and two light chains, each containing a variable region that specifically binds to CEACAM5. The antibody has a molecular weight of approximately 150 kDa and belongs to the IgG1 isotype.

Activity:

The primary function of Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade is to bind to CEACAM5, a cell surface glycoprotein that is overexpressed in various types of cancer cells. This binding inhibits the growth and survival of cancer cells, making it a potential therapeutic target for cancer treatment. Additionally, this biosimilar has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), further enhancing its anti- cancer activity.

Application:

Due to its specific targeting of CEACAM5, Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade has potential applications in the treatment of various types of cancer, including colorectal, lung, and breast cancer. It can be used as a standalone therapy or in combination with other cancer treatments, such as chemotherapy or radiation therapy.

Research Grade:

Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade is specifically designed for use in research and development purposes. It is not intended for therapeutic use in humans, but rather for in vitro and in vivo studies to further understand its mechanism of action and potential applications. This research grade biosimilar is produced under strict quality control measures to ensure its purity and consistency.

Advantages:

Compared to the original Altumomab antibody, the biosimilar offers several advantages. Firstly, it is more cost-effective, making it more accessible for research and development purposes. Secondly, it has a higher binding affinity to CEACAM5, leading to a stronger anti- cancer activity. Lastly, as a biosimilar, it has been extensively studied and has shown similar efficacy and safety profiles to the original antibody.

Conclusion:

In summary, Altumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade is a recombinant monoclonal antibody that specifically targets CEACAM5, a cell surface protein overexpressed in various types of cancer. Its structure, activity, and potential applications make it a promising biosimilar for cancer treatment. Further research and development are needed to fully understand its potential and to bring it to the market as a therapeutic option for cancer patients.